# Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

> **NCT03534635** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pembrolizumab - additional treatment

## Key facts

- **NCT ID:** NCT03534635
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03534635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03534635, "Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03534635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*